Grünenthal looks beyond pain for transformative deals

January 24, 2017 Christoph Graener

Speaking at the 2017 Biotech Showcase™ in San Francisco, Grünenthal CEO Gabriel Baertschi reveals his ambition to grow the company from its current EUR 1.4 billion a year revenues to EUR 2 billion by 2022, launching four new medicines by that date, consolidating its position as a leader in pain therapeutics, while entering new areas. Consequently, he was at the meeting seeking new opportunities in indications adjacent to pain including inflammation, arthritis, gout, as well as Parkinson’s disease and rare diseases such as Duchenne muscular dystrophy. Looking at both early stage preclinical projects and later stage clinical assets, Baertschi is keen to expand the company’s global footprint. Already with a significant presence in Europe and Latin America, the company wants to expand in the US while entering the Japanese market for the first time

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Gabriel Baertschi – CEO, Grünenthal Group

Previous Article
Flexion gears up to commercialize Zilretta

Flexion CEO Mike Clayman shares expectations for regulatory review of recently-filed Zilretta for knee oste...

Next Article
Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017
Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporter...